Sergey Rekhtman
Dermatology · New Hyde Park, NYNPI 1417311192
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,235 of the $11,732 with a category attached, or 78.7%. Sun Pharmaceutical Industries Inc. accounts for 75.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $11,009 and has fallen 96.4% since, to $393 in 2025.
Across 20 payments — averaging $586.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$9K
- Boehringer Ingelheim$2K
- Johnson & Johnson$211
- Amgen$150
- AbbVie$111
What the payments were for
- Consulting fees$9,23579%
- Travel & lodging$1,30211%
- Food & beverage$1,19610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 13 | $8,894 |
| Boehringer Ingelheim | 2 | $2,366 |
| Johnson & Johnson | 2 | $211 |
| Amgen | 1 | $150 |
| AbbVie | 2 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,732 in reported general payments places this provider in the 75th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 52 | $201,204 |
| ErivedgeVismodegib | 12 | $168,269 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $161,617 |
| Halobetasol Propionate | 50 | $3,081 |
| Clobetasol Propionate | 47 | $2,684 |
| Tacrolimus | 27 | $2,656 |
| Ketoconazole | 85 | $1,484 |
| Triamcinolone Acetonide | 132 | $1,148 |
| Mycophenolate Mofetil | 16 | $946 |
| Metronidazole | 16 | $874 |
| Clindamycin Phosphate | 22 | $861 |
| Ciclopirox | 19 | $705 |
| Fluorouracil | 11 | $663 |
| MethotrexateMethotrexate Sodium | 14 | $313 |
| Hydrocortisone | 43 | $174 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Hyde Park
- Amit GargNew Hyde Park$453K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.